Sotirios Tsimikas

List of Publications by Year in descending order

282 papers	25,192 citations	3515 90 h-index	8370 147 g-index
288 all docs	288 docs citations	288 times ranked	17910 citing authors

#	Article	IF	Citations
1	Association of lipoprotein(a) with intrinsic and on-clopidogrel platelet reactivity. Journal of Thrombosis and Thrombolysis, 2022, 53, 1-9.	1.0	6
2	Atherothrombotic factors and atherosclerotic cardiovascular events: the multi-ethnic study of atherosclerosis. European Heart Journal, 2022, 43, 971-981.	1.0	23
3	Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. European Heart Journal, 2022, 43, 1401-1412.	1.0	78
4	Lipoprotein(a), venous thromboembolism and COVID-19: A pilot study. Atherosclerosis, 2022, 341, 43-49.	0.4	28
5	Lipoprotein(a) and CT Angiography. Journal of the American College of Cardiology, 2022, 79, 234-237.	1.2	3
6	Trends in testing and prevalence of elevated Lp(a) among patients with aortic valve stenosis. Atherosclerosis, 2022, 349, 144-150.	0.4	9
7	Lipoprotein(a) and Coronary Calcium. Journal of the American College of Cardiology, 2022, 79, 769-771.	1.2	3
8	Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol. Journal of the American College of Cardiology, 2022, 79, 1035-1046.	1.2	65
9	Generation of cardio-protective antibodies after pneumococcal polysaccharide vaccine: Early results from a randomised controlled trial. Atherosclerosis, 2022, 346, 68-74.	0.4	7
10	Interventional hepatic apoC-III knockdown improves atherosclerotic plaque stability and remodeling by triglyceride lowering. JCI Insight, 2022, 7, .	2.3	7
11	Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia. Journal of Clinical Lipidology, 2022, 16, 617-625.	0.6	15
12	Oxidized phospholipids on apolipoprotein B-100 versus plasminogen and risk of coronary heart disease in the PROCARDIS study. Atherosclerosis, 2022, 354, 15-22.	0.4	9
13	Development and validation of an isoform-independent monoclonal antibodyâ€“based ELISA for measurement of lipoprotein(a). Journal of Lipid Research, 2022, 63, 100239.	2.0	10
14	Genome-Wide Association Study HighlightsAPOHas a Novel Locus for Lipoprotein(a) Levels. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 458-464.	1.1	29
15	Effect of bariatric surgery on plasma levels of oxidised phospholipids, biomarkers of oxidised LDL and lipoprotein(a). Journal of Clinical Lipidology, 2021, 15, 320-331.	0.6	13
16	Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data. ESC Heart Failure, 2021, 8, 652-661.	1.4	43
17	Novel method for quantification of lipoprotein(a)-cholesterol: implications for improving accuracy of LDL-C measurements. Journal of Lipid Research, 2021, 62, 100053.	2.0	62
18	Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy. Neurology and Therapy, 2021, 10, 375-389.	1.4	34

#	Article	IF	Citations
19	Glucose Control in Patients UndergoingÂPCI. JACC: Cardiovascular Interventions, 2021, 14, 398-400.	1.1	0
20	Intracellular AIBP (Apolipoprotein A-I Binding Protein) Regulates Oxidized LDL (Low-Density) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 707 T 2021, 41, e82-e96.	1.1	18
21	Emerging RNA Therapeutics to Lower Blood Levels of Lp(a). Journal of the American College of Cardiology, 2021, 77, 1576-1589.	1.2	86
22	Prevalence and influence of LPA gene variants and isoform size on the Lp(a)-lowering effect of pelacarsen. Atherosclerosis, 2021, 324, 102-108.	0.4	19
23	Antisense Inhibition of Angiotensinogen With IONIS-AGT-LRx. JACC Basic To Translational Science, 2021, 6, 485-496.	1.9	30
24	Elevated lipoprotein(a) and the risk of stroke in children, young adults, and the elderly. European Heart Journal, 2021, 42, 2197-2200.	1.0	14
25	Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Diabetes and Endocrinology,the, 2021, 9, 264-275.	5.5	109
26	Neutralization of oxidized phospholipids attenuates ageâ€associated bone loss in mice. Aging Cell, 2021, 20, e13442.	3.0	17
27	PCSK9 Inhibition and Oxidized Phospholipids. Journal of the American College of Cardiology, 2021, 78, 1288-1289.	1.2	6
28	Always Present, But Now Rediscovered. JACC: Cardiovascular Interventions, 2021, 14, 2069-2072.	1.1	2
29	Longitudinal Assessment of Lipoprotein(a) Levels in Perinatally HIV-Infected Children and Adolescents. Viruses, 2021, 13, 2067.	1.5	3
30	PCSK9 Activity Is Potentiated Through HDL Binding. Circulation Research, 2021, 129, 1039-1053.	2.0	13
31	Oxidized Phospholipids Promote NETosis and Arterial Thrombosis in LNK(SH2B3) Deficiency. Circulation, 2021, 144, 1940-1954.	1.6	33
32	Statins and increases in Lp(a): an inconvenient truth that needs attention. European Heart Journal, 2020, 41, 192-193.	1.0	20
33	Statin therapy increases lipoprotein(a) levels. European Heart Journal, 2020, 41, 2275-2284.	1.0	265
34	Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial. Circulation, 2020, 141, 624-636.	1.6	155
35	Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After AcuteÂCoronary Syndrome. Journal of the American College of Cardiology, 2020, 75, 133-144.	1.2	296
36	Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. New England Journal of Medicine, 2020, 382, 244-255.	13.9	559

#	Article	IF	Citations
37	Neutralization of Oxidized Phospholipids Ameliorates Non-alcoholic Steatohepatitis. Cell Metabolism, 2020, 31, 189-206.e8.	7.2	113
38	Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. European Heart Journal, 2020, 41, 4245-4255.	1.0	117
39	Generation and characterization of LPA-KIV9, a murine monoclonal antibody binding a single site on apolipoprotein (a). Journal of Lipid Research, 2020, 61, 1263-1270.	2.0	8
40	Lowâ€Ðensity Lipoprotein Cholesterol Corrected for Lipoprotein(a) Cholesterol, Risk Thresholds, and Cardiovascular Events. Journal of the American Heart Association, 2020, 9, e016318.	1.6	26
41	Lipoprotein(a) and Its Potential Association with Thrombosis and Inflammation in COVID-19: a Testable Hypothesis. Current Atherosclerosis Reports, 2020, 22, 48.	2.0	55
42	Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia. European Heart Journal, 2020, 41, 3936-3945.	1.0	188
43	Short-term regulation of hematopoiesis by lipoprotein(a) results in the production of pro-inflammatory monocytes. International Journal of Cardiology, 2020, 315, 81-85.	0.8	13
44	Atherogenic Lipoprotein(a) Increases Vascular Glycolysis, Thereby Facilitating Inflammation and Leukocyte Extravasation. Circulation Research, 2020, 126, 1346-1359.	2.0	96
45	The dedicated â€œLp(a) clinicâ€: A concept whose time has arrived?. Atherosclerosis, 2020, 300, 1-9.	0.4	52
46	ApoCIII-Lp(a) complexes in conjunction with Lp(a)-OxPL predict rapid progression of aortic stenosis. Heart, 2020, 106, 738-745.	1.2	28
47	Ancient Remedy for a Modern Disease. JACC Basic To Translational Science, 2020, 5, 50-52.	1.9	2
48	From traditional pharmacological towards nucleic acid-based therapies for cardiovascular diseases. European Heart Journal, 2020, 41, 3884-3899.	1.0	58
49	High-Density Lipoproteins Are the Main Carriers of PCSK9 in the Circulation. Journal of the American College of Cardiology, 2020, 75, 1495-1497.	1.2	9
50	Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a). European Heart Journal, 2020, 41, 2262-2271.	1.0	65
51	A Neutralizing Antibody Targeting Oxidized Phospholipids Promotes Bone Anabolism in Chow-Fed Young Adult Mice. Journal of Bone and Mineral Research, 2020, 36, 170-185.	3.1	10
52	The interconnection between lipoprotein(a), lipoprotein(a) cholesterol and true LDL-cholesterol in the diagnosis of familial hypercholesterolemia. Current Opinion in Lipidology, 2020, 31, 305-312.	1.2	11
53	microRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production. JCI Insight, 2020, 5, .	2.3	29
54	Reduction of myocardial ischaemiaâ€“reperfusion injury by inactivating oxidized phospholipids. Cardiovascular Research, 2019, 115, 179-189.	1.8	61

#	Article	IF	Citations
55	Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome. New England Journal of Medicine, 2019, 381, 531-542.	13.9	359
56	N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels. European Heart Journal, 2019, 40, 2785-2796.	1.0	159
57	PCSK9 loss-of-function variants and Lp(a) phenotypes among black US adults. Journal of Lipid Research, 2019, 60, 1946-1952.	2.0	8
58	The challenges of measuring Lp(a): A fight against Hydra?. Atherosclerosis, 2019, 289, 181-183.	0.4	18
59	Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis. Journal of Lipid Research, 2019, 60, 2082-2089.	2.0	35
60	Diversification and CXCR4-Dependent Establishment of the Bone Marrow B-1a Cell Pool Governs Atheroprotective IgM Production Linked to Human Coronary Atherosclerosis. Circulation Research, 2019, 125, e55-e70.	2.0	42
61	Lipid-Lowering Agents. Circulation Research, 2019, 124, 386-404.	2.0	124
62	Potential Causality and Emerging Medical Therapies for Lipoprotein(a) and Its Associated Oxidized Phospholipids in Calcific Aortic Valve Stenosis. Circulation Research, 2019, 124, 405-415.	2.0	57
63	Lipoprotein(a) in Patients Undergoing Transcatheter Aortic Valve Replacement. Angiology, 2019, 70, 332-336.	0.8	6
64	Lipoprotein(a) and Oxidized Phospholipids Promote Valve Calcification in Patients With AorticÂStenosis. Journal of the American College of Cardiology, 2019, 73, 2150-2162.	1.2	187
65	Lipoprotein(a), Oxidized Phospholipids, and Aortic Valve Microcalcification Assessed by 18F-Sodium Fluoride Positron Emission Tomography and Computed Tomography. CJC Open, 2019, 1, 131-140.	0.7	38
66	In Search of Patients With Elevated Lp(a). Journal of the American College of Cardiology, 2019, 73, 1040-1042.	1.2	3
67	A monoclonal antibody to assess oxidized cholesteryl esters associated with apoAI and apoB-100 lipoproteins in human plasma. Journal of Lipid Research, 2019, 60, 436-445.	2.0	7
68	Integrated Assessment of the Clinical Performance of GalNAc₃-Conjugated 2â€²-O-Methoxyethyl Chimeric Antisense Oligonucleotides: I. Human Volunteer Experience. Nucleic Acid Therapeutics, 2019, 29, 16-32.	2.0	85
69	Nanobody-Facilitated Multiparametric PET/MRI Phenotyping of Atherosclerosis. JACC: Cardiovascular Imaging, 2019, 12, 2015-2026.	2.3	66
70	Elevated Lipoprotein(a) in Perinatally HIV-Infected Children Compared With Healthy Ethnicity-Matched Controls. Open Forum Infectious Diseases, 2019, 6, ofz301.	0.4	3
71	Relationship between â€œLDL-Câ€, estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide. Journal of Clinical Lipidology, 2018, 12, 702-710.	0.6	53
72	Cell-specific discrimination of desmosterol and desmosterol mimetics confers selective regulation of LXR and SREBP in macrophages. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E4680-E4689.	3.3	76

#	Article	IF	Citations
73	PET/MR Imaging of Malondialdehyde-Acetaldehyde Epitopes With a HumanÂAntibody Detects ClinicallyÂRelevant Atherothrombosis. Journal of the American College of Cardiology, 2018, 71, 321-335.	1.2	39
74	Association of D-dimer with Plaque Characteristics and Plasma Biomarkers of Oxidation-Specific Epitopes in Stable Subjects with Coronary Artery Disease. Journal of Cardiovascular Translational Research, 2018, 11, 221-229.	1.1	14
75	Interleukin-1 genotypes modulate the long-term effect of lipoprotein(a) on cardiovascular events: The Ioannina Study. Journal of Clinical Lipidology, 2018, 12, 338-347.	0.6	18
76	NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated RiskÂofÂCardiovascular Disease and AorticÂStenosis. Journal of the American College of Cardiology, 2018, 71, 177-192.	1.2	337
77	In search of a physiological function of lipoprotein(a): causality of elevated Lp(a) levels and reduced incidence of type 2 diabetes. Journal of Lipid Research, 2018, 59, 741-744.	2.0	16
78	Temporal variability in lipoprotein(a) levels in patients enrolled in the placebo arms of IONIS-APO(a)Rx and IONIS-APO(a)-LRx antisense oligonucleotide clinical trials. Journal of Clinical Lipidology, 2018, 12, 122-129.e2.	0.6	36
79	The Effects of 2â€²-O-Methoxyethyl Oligonucleotides on Renal Function in Humans. Nucleic Acid Therapeutics, 2018, 28, 10-22.	2.0	55
80	Association of Mild to Moderate Aortic Valve Stenosis Progression With Higher Lipoprotein(a) and Oxidized Phospholipid Levels. JAMA Cardiology, 2018, 3, 1212.	3.0	76
81	Relationship of lipoprotein-associated apolipoprotein C-III with lipid variables and coronary artery disease risk: The EPIC-Norfolk prospective population study. Journal of Clinical Lipidology, 2018, 12, 1493-1501.e11.	0.6	7
82	Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. Lancet, The, 2018, 392, 1311-1320.	6.3	355
83	RNA-targeted therapeutics for lipid disorders. Current Opinion in Lipidology, 2018, 29, 459-466.	1.2	54
84	Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size. Journal of Clinical Lipidology, 2018, 12, 1313-1323.	0.6	66
85	Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice. Nature, 2018, 558, 301-306.	13.7	359
86	Oxidation-specific epitopes restrain bone formation. Nature Communications, 2018, 9, 2193.	5.8	41
87	Elevated Lp(a) and Abdominal Aortic Aneurysm. Angiology, 2017, 68, 96-98.	0.8	3
88	Lipoprotein(a) Mass Levels Increase Significantly According to APOE Genotype. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 580-588.	1.1	76
89	Oxidized Phospholipids on ApolipoproteinÂB-100 and RecurrentÂIschemic Events Following Stroke or Transient Ischemic Attack. Journal of the American College of Cardiology, 2017, 69, 147-158.	1.2	46
90	Identification of a novel series of anti-inflammatory and anti-oxidative phospholipid oxidation products containing the cyclopentenone moiety in vitro and in vivo: Implication in atherosclerosis. Journal of Biological Chemistry, 2017, 292, 5378-5391.	1.6	30

#	Article	IF	Citations
91	The Prevalence of Lipoprotein(a) Measurement and Degree of Elevation Among 2710 Patients With Calcific Aortic Valve Stenosis in an Academic Echocardiography Laboratory Setting. Angiology, 2017, 68, 795-798.	0.8	10
92	A Test in Context: Lipoprotein(a). Journal of the American College of Cardiology, 2017, 69, 692-711.	1.2	668
93	Very-Low-Density Lipoproteinâ€“Associated Apolipoproteins Predict Cardiovascular Events and Are Lowered by InhibitionÂofÂAPOC-III. Journal of the American College of Cardiology, 2017, 69, 789-800.	1.2	150
94	Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a mendelian randomisation analysis. Lancet Diabetes and Endocrinology,the, 2017, 5, 524-533.	5.5	165
95	Apolipoprotein C-III Levels and Incident Coronary Artery Disease Risk. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1206-1212.	1.1	56
96	Relationship of Autoantibodies to MDA-LDL and ApoB-Immune Complexes to Sex, Ethnicity, Subclinical Atherosclerosis, and Cardiovascular Events. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1213-1221.	1.1	50
97	Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides. New England Journal of Medicine, 2017, 377, 222-232.	13.9	482
98	Oxidized Phospholipids and Risk of Calcific Aortic Valve Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1570-1578.	1.1	60
99	Novel Lipoprotein(a) Catabolism Pathway via Apolipoprotein(a) Recycling. Circulation Research, 2017, 120, 1050-1052.	2.0	14
100	Lipoprotein(a) Improves Cardiovascular Risk PredictionÂBased on Established Risk Algorithms. Journal of the American College of Cardiology, 2017, 69, 1513-1515.	1.2	31
101	Autoantibodies and immune complexes to oxidation-specific epitopes and progression of aortic stenosis: Results from the ASTRONOMER trial. Atherosclerosis, 2017, 260, 1-7.	0.4	6
102	Adenoviral intramyocardial VEGF-DÎ”NÎ”C gene transfer increases myocardial perfusion reserve in refractory angina patients: a phase I/IIa study with 1-year follow-up. European Heart Journal, 2017, 38, 2547-2555.	1.0	109
103	Lipoprotein(a)-Associated Molecules AreÂProminent Components in Plasma andÂValve Leaflets in Calcific Aortic ValveÂStenosis. JACC Basic To Translational Science, 2017, 2, 229-240.	1.9	61
104	Plasma Proteomics for Epidemiology. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	17
105	Threshold Effects of Circulating Angiopoietin-Like 3 Levels on Plasma Lipoproteins. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3340-3348.	1.8	29
106	Lipoprotein(a) and incident type-2 diabetes: results from the prospective Bruneck study and a meta-analysis of published literature. Cardiovascular Diabetology, 2017, 16, 38.	2.7	66
107	LPA Gene, Ethnicity, and Cardiovascular Events. Circulation, 2017, 135, 251-263.	1.6	83
108	Lipoprotein(a). Current Opinion in Endocrinology, Diabetes and Obesity, 2016, 23, 157-164.	1.2	49

#	Article	IF	Citations
109	Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis. Current Opinion in Cardiology, 2016, 31, 440-450.	0.8	55
110	Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a). Journal of Clinical Lipidology, 2016, 10, 594-603.	0.6	88
111	Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia. Journal of Clinical Lipidology, 2016, 10, 1011-1021.	0.6	104
112	Protective Role for B-1b B Cells and IgM in Obesity-Associated Inflammation, Glucose Intolerance, and Insulin Resistance. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 682-691.	1.1	69
113	Acute and long-term effect of percutaneous coronary intervention on serially-measured oxidative, inflammatory, and coagulation biomarkers in patients with stable angina. Journal of Thrombosis and Thrombolysis, 2016, 41, 569-580.	1.0	15
114	PCSK9 Association With Lipoprotein(a). Circulation Research, 2016, 119, 29-35.	2.0	99
115	Plasma Levels of Advanced Glycation End Products Are Related to the Clinical Presentation and Angiographic Severity of Symptomatic Lower Extremity Peripheral Arterial Disease. International Journal of Angiology, 2016, 25, 044-053.	0.2	3
116	The role of lipoprotein(a) in progression of renal disease: Causality or reverse causality?. Journal of Diabetes and Its Complications, 2016, 30, 755-757.	1.2	1
117	Lipoprotein(a)-cholesterol levels estimated by vertical auto profile correlate poorly with Lp(a) mass in hyperlipidemic subjects: Implications for clinical practice interpretation of Lp(a)-mediated risk. Journal of Clinical Lipidology, 2016, 10, 1389-1396.	0.6	20
118	Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans. Circulation, 2016, 134, 611-624.	1.6	396
119	The re-emergence of lipoprotein(a) in a broader clinical arena. Progress in Cardiovascular Diseases, 2016, 59, 135-144.	1.6	24
120	Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet, The, 2016, 388, 2239-2253.	6.3	584
121	Immune cell screening of a nanoparticle library improves atherosclerosis therapy. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E6731-E6740.	3.3	95
122	Prevalence of Elevated Lp(a) Mass Levels and Patient Thresholds in 532 359 Patients in the United States. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 2239-2245.	1.1	132
123	Population and assay thresholds for the predictive value of lipoprotein (a) for coronary artery disease: the EPIC-Norfolk Prospective Population Study. Journal of Lipid Research, 2016, 57, 697-705.	2.0	24
124	InÂVivo PET Imaging of HDL in MultipleÂAtherosclerosisÂModels. JACC: Cardiovascular Imaging, 2016, 9, 950-961.	2.3	78
125	Circulating levels of plasminogen and oxidized phospholipids bound to plasminogen distinguish between atherothrombotic and non-atherothrombotic myocardial infarction. Journal of Thrombosis and Thrombolysis, 2016, 42, 61-76.	1.0	28
126	Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results. Journal of Lipid Research, 2016, 57, 706-713.	2.0	83

#	Article	IF	Citations
127	Experimental Animal Models Evaluating the Causal Role of Lipoprotein(a) in Atherosclerosis and Aortic Stenosis. Cardiovascular Drugs and Therapy, 2016, 30, 75-85.	1.3	31
128	Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans. Journal of Lipid Research, 2016, 57, 340-351.	2.0	112
129	Retrieval of a detached transseptal sheath tip from a right pulmonary artery branch following catheter ablation. Catheterization and Cardiovascular Interventions, 2015, 86, 1131-1135.	0.7	3
130	â€˜LDL-Câ€™â€Š=â€ŠLDL-Câ€Š+â€ŠLp(a)-C. Current Opinion in Lipidology, 2015, 26, 169-178.	1.2	122
131	Mipomersen, an Antisense Oligonucleotide to Apolipoprotein B-100, Reduces Lipoprotein(a) in Various Populations With Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 689-699.	1.1	165
132	Mechanistic insights into Lp(a)-induced IL-8 expression: a role for oxidized phospholipid modification of apo(a). Journal of Lipid Research, 2015, 56, 2273-2285.	2.0	85
133	Heme Oxygenase-1 Gene Promoter Microsatellite Polymorphism Is Associated With Progressive Atherosclerosis and Incident Cardiovascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 229-236.	1.1	49
134	Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet, The, 2015, 386, 1472-1483.	6.3	386
135	B-1b Cells Secrete Atheroprotective IgM and Attenuate Atherosclerosis. Circulation Research, 2015, 117, e28-39.	2.0	111
136	Manganese G8 dendrimers targeted to oxidationâ€specific epitopes: In vivo MR imaging of atherosclerosis. Journal of Magnetic Resonance Imaging, 2015, 41, 797-805.	1.9	25
137	Relationship of Oxidized Phospholipids onÂApolipoprotein B-100 to CardiovascularÂOutcomes in Patients Treated With Intensive Versus ModerateÂAtorvastatin Therapy. Journal of the American College of Cardiology, 2015, 65, 1286-1295.	1.2	61
138	Apolipoprotein C-III: From Pathophysiology to Pharmacology. Trends in Pharmacological Sciences, 2015, 36, 675-687.	4.0	144
139	Heritability of Biomarkers of Oxidized Lipoproteins. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 1704-1711.	1.1	44
140	HDL-C, ABCA1-mediated cholesterol efflux, and lipoprotein(a): insights into a potential novel physiologic role of lipoprotein(a). Journal of Lipid Research, 2015, 56, 1241-1244.	2.0	2
141	Invasive Cardiologists Are Exposed to Greater Left Sided Cranial Radiation. JACC: Cardiovascular Interventions, 2015, 8, 1197-1206.	1.1	93
142	Oxidized Phospholipids, Lipoprotein(a),Âand Progression of CalcificÂAortic ValveÂStenosis. Journal of the American College of Cardiology, 2015, 66, 1236-1246.	1.2	295
143	Circulating microparticles carry oxidation-specific epitopes and are recognized by natural IgM antibodies. Journal of Lipid Research, 2015, 56, 440-448.	2.0	96
144	Prevalence of coronary artery spasm after stent placement and its association with inflammation. International Journal of Cardiology, 2015, 179, 252-255.	0.8	16

#	Article	IF	Citations
145	Molecular Imaging of Oxidation-Specific Epitopes to Detect High-Risk Atherosclerotic Plaques. , 2015, , 121-154.		0
146	Lipoprotein(A) with An Intact Lysine Binding Site Protects the Retina From an Age-Related Macular Degeneration Phenotype in Mice (An American Ophthalmological Society Thesis). Transactions of the American Ophthalmological Society, 2015, 113, T5.	1.4	9
147	Abstract 21: B-1b Cells Secrete Atheroprotective IgM and Attenuate Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, .	1.1	0
148	Leucocyte Telomere Length and Risk of Type 2 Diabetes Mellitus: New Prospective Cohort Study and Literature-Based Meta-Analysis. PLoS ONE, 2014, 9, e112483.	1.1	174
149	Imaging of Oxidation-Specific Epitopes with Targeted Nanoparticles to Detect High-Risk Atherosclerotic Lesions: Progress and Future Directions. Journal of Cardiovascular Translational Research, 2014, 7, 719-736.	1.1	18
150	What is the ultimate test that lowering lipoprotein(a) is beneficial for cardiovascular disease and aortic stenosis?. Current Opinion in Lipidology, 2014, 25, 423-430.	1.2	22
151	Release and Capture of Bioactive Oxidized Phospholipids and Oxidized Cholesteryl Esters During Percutaneous Coronary and Peripheral Arterial Interventions in Humans. Journal of the American College of Cardiology, 2014, 63, 1961-1971.	1.2	88
152	New Therapeutic Targets for Calcific Aortic Valve Stenosis. Journal of the American College of Cardiology, 2014, 63, 478-480.	1.2	38
153	Highlights of the Year in JACC 2013. Journal of the American College of Cardiology, 2014, 63, 570-602.	1.2	2
154	The Severe Hypercholesterolemia Phenotype. Journal of the American College of Cardiology, 2014, 63, 1935-1947.	1.2	153
155	The Association Between Circulating Lipoprotein(a) and Type 2 Diabetes: Is It Causal?. Diabetes, 2014, 63, 332-342.	0.3	82
156	Lipoprotein(a) for Risk Assessment in Patients With Established Coronary Artery Disease. Journal of the American College of Cardiology, 2014, 63, 520-527.	1.2	152
157	Atheroprotective immunization with malondialdehyde-modified LDL is hapten specific and dependent on advanced MDA adducts: implications for development of an atheroprotective vaccine. Journal of Lipid Research, 2014, 55, 2137-2155.	2.0	47
158	Discrimination and Net Reclassification of Cardiovascular Risk With Lipoprotein(a). Journal of the American College of Cardiology, 2014, 64, 851-860.	1.2	231
159	Lipoprotein Apheresis and Acute Reduction of Arterial Inflammation. Journal of the American College of Cardiology, 2014, 64, 1427-1429.	1.2	2
160	Pro-Inflammatory Interleukin-1 Genotypes Potentiate the Risk of Coronary Artery Disease and Cardiovascular Events Mediated by Oxidized Phospholipids and Lipoprotein(a). Journal of the American College of Cardiology, 2014, 63, 1724-1734.	1.2	110
161	Helix-Loop-Helix Factor Inhibitor of Differentiation 3 Regulates Interleukin-5 Expression and B-1a B Cell Proliferation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 2771-2779.	1.1	46
162	Secretory Phospholipase A2-IIA and Cardiovascular Disease. Journal of the American College of Cardiology, 2013, 62, 1966-1976.	1.2	115

#	Article	IF	Citations
163	Oxidation-specific epitopes and immunological responses: Translational biotheranostic implications for atherosclerosis. Current Opinion in Pharmacology, 2013, 13, 168-179.	1.7	74
164	MCP-1 binds to oxidized LDL and is carried by lipoprotein(a) in human plasma. Journal of Lipid Research, 2013, 54, 1877-1883.	2.0	76
165	Effects of pitavastatin and atorvastatin on lipoprotein oxidation biomarkers in patients with dyslipidemia. Atherosclerosis, 2013, 226, 161-164.	0.4	41
166	Tracking Oxidatively Stressed Cardiac Stem Cells With MolecularÂImaging. JACC: Cardiovascular Imaging, 2013, 6, 803-805.	2.3	0
167	Highlights of the Year in JACC 2012. Journal of the American College of Cardiology, 2013, 61, 357-385.	1.2	1
168	Oxidation-Specific Biomarkers and Risk of Peripheral Artery Disease. Journal of the American College of Cardiology, 2013, 61, 2169-2179.	1.2	71
169	Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a). Journal of Lipid Research, 2013, 54, 2815-2830.	2.0	174
170	Oxidation-specific epitopes as targets for biotheranostic applications in humans. Current Opinion in Lipidology, 2013, 24, 426-437.	1.2	31
171	Polyoxygenated Cholesterol Ester Hydroperoxide Activates TLR4 and SYK Dependent Signaling in Macrophages. PLoS ONE, 2013, 8, e83145.	1.1	44
172	Adaptive immunity in atherogenesis: new insights and therapeutic approaches. Journal of Clinical Investigation, 2013, 123, 27-36.	3.9	163
173	Peptide mimotopes of malondialdehyde epitopes for clinical applications in cardiovascular disease. Journal of Lipid Research, 2012, 53, 1316-1326.	2.0	44
174	Lipoprotein(a) and Risk of Coronary, Cerebrovascular, and Peripheral Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 3058-3065.	1.1	146
175	Emerging therapeutic agents to lower lipoprotein (a) levels. Current Opinion in Lipidology, 2012, 23, 560-568.	1.2	56
176	Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions. Journal of Lipid Research, 2012, 53, 2773-2790.	2.0	131
177	Acute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemia. Journal of Lipid Research, 2012, 53, 1670-1678.	2.0	53
178	Lipid Oxidation in Carriers of Lecithin:Cholesterol Acyltransferase Gene Mutations. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 3066-3075.	1.1	27
179	B-Cell Aortic Homing and Atheroprotection Depend on Id3. Circulation Research, 2012, 110, e1-12.	2.0	102
180	Oxidation-Specific Biomarkers, Prospective 15-Year Cardiovascular and Stroke Outcomes, and Net Reclassification of Cardiovascular Events. Journal of the American College of Cardiology, 2012, 60, 2218-2229.	1.2	187

#	Article	IF	Citations
181	Regulated Accumulation of Desmosterol Integrates Macrophage Lipid Metabolism and Inflammatory Responses. Cell, 2012, 151, 138-152.	13.5	487
182	Effect of an oral astaxanthin prodrug (CDX-085) on lipoprotein levels and progression of atherosclerosis in LDLRâˆ'/âˆ' and ApoEâˆ'/âˆ' mice. Atherosclerosis, 2012, 222, 99-105.	0.4	32
183	Lipoprotein oxidation biomarkers for cardiovascular risk: what does the future hold?. Expert Review of Cardiovascular Therapy, 2012, 10, 399-402.	0.6	4
184	In Vivo Detection of Oxidation-Specific Epitopes in Atherosclerotic Lesions Using Biocompatible Manganese Molecular Magnetic Imaging Probes. Journal of the American College of Cardiology, 2012, 59, 616-626.	1.2	55
185	Highlights of the Year in JACC 2011. Journal of the American College of Cardiology, 2012, 59, 503-537.	1.2	1
186	The Clinical Emergence of Optical Coherence Tomography. Journal of the American College of Cardiology, 2012, 59, 1090-1092.	1.2	5
187	Oxidized Phospholipids Are Present on Plasminogen, Affect Fibrinolysis, and Increase Following Acute Myocardial Infarction. Journal of the American College of Cardiology, 2012, 59, 1426-1437.	1.2	64
188	Increased Expression of Oxidation-Specific Epitopes and Apoptosis Are Associated With Haptoglobin Genotype. Journal of the American College of Cardiology, 2012, 60, 112-119.	1.2	36
189	Lipoprotein(a) as a Potential Causal Genetic Risk Factor of Cardiovascular Disease. Journal of the American College of Cardiology, 2012, 60, 716-721.	1.2	190
190	Regression of Inflammation in Atherosclerosis by the LXR Agonist R211945. JACC: Cardiovascular Imaging, 2012, 5, 819-828.	2.3	68
191	Phospholipase A ₂ Enzymes, High-Dose Atorvastatin, and Prediction of Ischemic Events After Acute Coronary Syndromes. Circulation, 2012, 125, 757-766.	1.6	51
192	The role of oxidized phospholipids, lipoprotein (a) and biomarkers of oxidized lipoproteins in chronically occluded coronary arteries in sudden cardiac death and following successful percutaneous revascularization. Cardiovascular Revascularization Medicine, 2012, 13, 11-19.	0.3	25
193	Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature, 2011, 478, 76-81.	13.7	469
194	Targeted Iron Oxide Particles for In Vivo Magnetic Resonance Detection of Atherosclerotic Lesions With Antibodies Directed to Oxidation-Specific Epitopes. Journal of the American College of Cardiology, 2011, 57, 337-347.	1.2	108
195	Antisense Oligonucleotide Lowers Plasma Levels of Apolipoprotein (a) and Lipoprotein (a) in Transgenic Mice. Journal of the American College of Cardiology, 2011, 57, 1611-1621.	1.2	113
196	Highlights of the Year in JACC 2010. Journal of the American College of Cardiology, 2011, 57, 480-514.	1.2	1
197	Human Oxidation-Specific Antibodies Reduce Foam Cell Formation and Atherosclerosis Progression. Journal of the American College of Cardiology, 2011, 58, 1715-1727.	1.2	100
198	Lipoprotein-associated phospholipase A2 mass and activity in children with heterozygous familial hypercholesterolemia and unaffected siblings: Effect of pravastatin. Journal of Clinical Lipidology, 2011, 5, 50-56.	0.6	14

#	Article	IF	Citations
199	Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists. Journal of Clinical Lipidology, 2011, 5, 338-367.	0.6	235
200	Pioglitazone Modulates Vascular Inflammation in Atherosclerotic Rabbits. JACC: Cardiovascular Imaging, 2011, 4, 1100-1109.	2.3	73
201	Oxidation-Specific Epitopes Are Danger-Associated Molecular Patterns Recognized by Pattern Recognition Receptors of Innate Immunity. Circulation Research, 2011, 108, 235-248.	2.0	527
202	Oxidative Modification of Lipoproteins: Mechanisms, Role in Inflammation and Potential Clinical Applications in Cardiovascular Disease. Current Pharmaceutical Design, 2011, 17, 27-37.	0.9	148
203	Imaging of Oxidation-Specific Epitopes in Atherosclerosis and Macrophage-Rich Vulnerable Plaques. Current Cardiovascular Imaging Reports, 2011, 4, 4-16.	0.4	27
204	Successful treatment of in-stent restenosis of a covered stent graft with a paclitaxel-eluting stent. Journal of Cardiology Cases, 2011, 4, e13-e15.	0.2	1
205	Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study. Journal of Lipid Research, 2011, 52, 1829-1836.	2.0	113
206	Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events. Biomarkers in Medicine, 2011, 5, 673-694.	0.6	156
207	In vivo visualization and attenuation of oxidized lipid accumulation in hypercholesterolemic zebrafish. Journal of Clinical Investigation, 2011, 121, 4861-4869.	3.9	81
208	Renal artery plaque composition is associated with changes in renal frame count following renal artery stenting. Journal of Invasive Cardiology, 2011, 23, 227-31.	0.4	7
209	Clinical Trial Report: The Presence and Rupture of Vulnerable Plaques in the Peripheral Circulation. Current Cardiovascular Imaging Reports, 2010, 3, 187-189.	0.4	1
210	Relation of Oxidative Biomarkers, Vascular Dysfunction, and Progression of Coronary Artery Calcium. American Journal of Cardiology, 2010, 105, 459-466.	0.7	59
211	Changes in lipoprotein(a), oxidized phospholipids, and LDL subclasses with a low-fat high-carbohydrate diet. Journal of Lipid Research, 2010, 51, 3324-3330.	2.0	67
212	Lipoprotein(a) accelerates atherosclerosis in uremic mice. Journal of Lipid Research, 2010, 51, 2967-2975.	2.0	18
213	Oxidized Cholesteryl Esters and Phospholipids in Zebrafish Larvae Fed a High Cholesterol Diet. Journal of Biological Chemistry, 2010, 285, 32343-32351.	1.6	80
214	Lipoprotein Modification and Macrophage Uptake: Role of Pathologic Cholesterol Transport in Atherogenesis. Sub-Cellular Biochemistry, 2010, 51, 229-251.	1.0	111
215	Oxidation-Specific Biomarkers, Lipoprotein(a), and Risk of Fatal and Nonfatal Coronary Events. Journal of the American College of Cardiology, 2010, 56, 946-955.	1.2	139
216	Atherogenic Lipids and Lipoproteins Trigger CD36-TLR2-Dependent Apoptosis in Macrophages Undergoing Endoplasmic Reticulum Stress. Cell Metabolism, 2010, 12, 467-482.	7.2	397

#	Article	IF	Citations
217	The I4399M variant of apolipoprotein(a) is associated with increased oxidized phospholipids on apolipoprotein B-100 particles. Atherosclerosis, 2010, 209, 498-503.	0.4	36
218	Effects of lowâ€fat, highâ€carbohydrate diet on plasma lipoprotein(a) and oxidized phospholipids. FASEB Journal, 2010, 24, lb365.	0.2	0
219	The role of innate immunity in atherogenesis. Journal of Lipid Research, 2009, 50, S388-S393.	2.0	122
220	Lipoprotein Oxidation and Modification. , 2009, , 93-110.		2
221	Relationship of Oxidized Phospholipids on Apolipoprotein B-100 Particles to Race/Ethnicity, Apolipoprotein(a) Isoform Size, and Cardiovascular Risk Factors. Circulation, 2009, 119, 1711-1719.	1.6	117
222	The role of oxidized phospholipids in atherosclerosis. Journal of Lipid Research, 2009, 50, S207-S212.	2.0	213
223	Spontaneous recanalization of a completely occluded saphenous vein graft two months following acute myocardial infarction with persistent one year patency. Journal of Thrombosis and Thrombolysis, 2009, 28, 101-105.	1.0	0
224	Estrogen-Eluting Stents. Journal of Cardiovascular Translational Research, 2009, 2, 240-244.	1.1	10
225	Aged garlic extract supplemented with B vitamins, folic acid and l-arginine retards the progression of subclinical atherosclerosis: A randomized clinical trial. Preventive Medicine, 2009, 49, 101-107.	1.6	129
226	Highlights of the Year in JACC 2008. Journal of the American College of Cardiology, 2009, 53, 373-398.	1.2	1
227	Relationship of Oxidized Phospholipids and Biomarkers of Oxidized Low-Density Lipoprotein With Cardiovascular Risk Factors, Inflammatory Biomarkers, and Effect of Statin Therapy in Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology, 2009, 53, 2186-2196.	1.2	91
228	Candidate biomarkers for the detection of coronary plaque destabilization and rupture. Current Atherosclerosis Reports, 2008, 10, 309-317.	2.0	11
229	In Vivo Markers of Oxidative Stress and Therapeutic Interventions. American Journal of Cardiology, 2008, 101, S34-S42.	0.7	61
230	The Influence of Pravastatin and Atorvastatin on Markers of Oxidative Stress in Hypercholesterolemic Humans. Journal of the American College of Cardiology, 2008, 51, 1653-1662.	1.2	104
231	Relationship Between Biomarkers of Oxidized Low-Density Lipoprotein, Statin Therapy, Quantitative Coronary Angiography, and Atheroma Volume. Journal of the American College of Cardiology, 2008, 52, 24-32.	1.2	92
232	The Evolution of Thienopyridine Therapy. Journal of the American College of Cardiology, 2008, 51, 2228-2229.	1.2	15
233	Antisense Oligonucleotide Directed to Human Apolipoprotein B-100 Reduces Lipoprotein(a) Levels and Oxidized Phospholipids on Human Apolipoprotein B-100 Particles in Lipoprotein(a) Transgenic Mice. Circulation, 2008, 118, 743-753.	1.6	143
234	Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study. European Heart Journal, 2008, 30, 107-115.	1.0	99

#	Article	IF	Citations
235	Targeted Molecular Probes for Imaging Atherosclerotic Lesions With Magnetic Resonance Using Antibodies That Recognize Oxidation-Specific Epitopes. Circulation, 2008, 117, 3206-3215.	1.6	170
236	A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. Journal of Lipid Research, 2008, 49, 2230-2239.	2.0	290
237	The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity. Current Opinion in Lipidology, 2008, 19, 369-377.	1.2	106
238	Abstract 3625: Targeted Ultra-Small Iron Oxide Particles for In Vivo MR Detection of Atherosclerotic Lesions Using Antibodies against Oxidized Low Density Lipoprotein. Circulation, 2008, 118, .	1.6	1
239	Oxidized Phospholipids, Lipoprotein(a), Lipoprotein-Associated Phospholipase A2 Activity, and 10-Year Cardiovascular Outcomes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 1788-1795.	1.1	220
240	Increased Plasma Oxidized Phospholipid:Apolipoprotein B-100 Ratio With Concomitant Depletion of Oxidized Phospholipids From Atherosclerotic Lesions After Dietary Lipid-Lowering. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 175-181.	1.1	78
241	New Insights Into the Role of Lipoprotein(a)-Associated Lipoprotein-Associated Phospholipase A ₂ in Atherosclerosis and Cardiovascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 2094-2099.	1.1	140
242	Deficiency of Glutathione Peroxidase-1 Accelerates the Progression of Atherosclerosis in Apolipoprotein E-Deficient Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 850-857.	1.1	169
243	Oxidized Low-Density Lipoprotein Biomarkers in Patients with End-Stage Renal Failure: Acute Effects of Hemodialysis. Blood Purification, 2007, 25, 457-465.	0.9	15
244	Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events. Journal of Lipid Research, 2007, 48, 425-433.	2.0	215
245	Emerging approaches for imaging vulnerable plaques in patients. Current Opinion in Biotechnology, 2007, 18, 73-82.	3.3	12
246	Nuclear imaging of the vulnerable plaque. , 2007, , 303-312.		0
247	Measures of Oxidative Stress. Clinics in Laboratory Medicine, 2006, 26, 571-590.	0.7	41
248	C-Reactive Protein and Other Emerging Blood Biomarkers to Optimize Risk Stratification of Vulnerable Patients. Journal of the American College of Cardiology, 2006, 47, C19-C31.	1.2	295
249	Imaging Vulnerable Plaque by Ultrasound. Journal of the American College of Cardiology, 2006, 47, C32-C39.	1.2	79
250	Oxidized Low-Density Lipoprotein in Children With Familial Hypercholesterolemia and Unaffected Siblings. Journal of the American College of Cardiology, 2006, 47, 1803-1810.	1.2	82
251	Oxidized Phospholipids Predict the Presence and Progression of Carotid and Femoral Atherosclerosis and Symptomatic Cardiovascular Disease. Journal of the American College of Cardiology, 2006, 47, 2219-2228.	1.2	174
252	Oxidized Low-Density Lipoprotein Autoantibodies, Chronic Infections, and Carotid Atherosclerosis in a Population-Based Study. Journal of the American College of Cardiology, 2006, 47, 2436-2443.	1.2	64

#	Article	IF	Citations
253	Clinical applications of circulating oxidized low-density lipoprotein biomarkers in cardiovascular disease. Current Opinion in Lipidology, 2006, 17, 502-509.	1.2	131
254	Oxidized low-density lipoprotein biomarkers in atherosclerosis. Current Atherosclerosis Reports, 2006, 8, 55-61.	2.0	71
255	Oxidative Biomarkers in the Diagnosis and Prognosis of Cardiovascular Disease. American Journal of Cardiology, 2006, 98, S9-S17.	0.7	87
256	Lipoproteins and Oxidation. , 2006, , 17-48.		3
257	Noninvasive imaging of atherosclerotic lesions in apolipoprotein E-deficient and low-density-lipoprotein receptor-deficient mice with annexin A5. Journal of Nuclear Medicine, 2006, 47, 1497-505.	2.8	68
258	Treatment of ischemic stroke complicating cardiac catheterization with systemic thrombolytic therapy. Catheterization and Cardiovascular Interventions, 2005, 66, 364-368.	0.7	10
259	Rapid progression of common femoral artery stenosis leading to development of ischemic foot ulcer following repeated ipsilateral arterial access. Catheterization and Cardiovascular Interventions, 2005, 66, 487-490.	0.7	1
260	Catheter-induced Vasospasm of Both the Right External Iliac and Right Coronary Arteries During Coronary Angiography. International Journal of Cardiovascular Imaging, 2005, 21, 481-485.	0.7	4
261	Consequences of Cholesteryl Ester Transfer Protein Inhibition in Patients With Familial Hypoalphalipoproteinemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, e133-4.	1.1	28
262	High-level lipoprotein [a] expression in transgenic mice: evidence for oxidized phospholipids in lipoprotein [a] but not in low density lipoproteins. Journal of Lipid Research, 2005, 46, 769-778.	2.0	52
263	Oxidized Phospholipids, Lp(a) Lipoprotein, and Coronary Artery Disease. New England Journal of Medicine, 2005, 353, 46-57.	13.9	636
264	Relationship of a comprehensive panel of plasma oxidized low-density lipoprotein markers to angiographic restenosis in patients undergoing percutaneous coronary intervention for stable angina. American Heart Journal, 2005, 150, 1007-1014.	1.2	30
265	High-Dose Atorvastatin Reduces Total Plasma Levels of Oxidized Phospholipids and Immune Complexes Present on Apolipoprotein B-100 in Patients With Acute Coronary Syndromes in the MIRACL Trial. Circulation, 2004, 110, 1406-1412.	1.6	209
266	Percutaneous Coronary Intervention Results in Acute Increases in Oxidized Phospholipids and Lipoprotein(a). Circulation, 2004, 109, 3164-3170.	1.6	229
267	Reduced In Vivo Aortic Uptake of Radiolabeled Oxidation-Specific Antibodies Reflects Changes in Plaque Composition Consistent With Plaque Stabilization. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 2307-2312.	1.1	80
268	Concomitant coronary and multiple arch vessel stenoses in patients treated with external beam radiation: Pathophysiological basis and endovascular treatment. Catheterization and Cardiovascular Interventions, 2004, 62, 385-390.	0.7	12
269	Severe ostial saphenous vein graft disease leading to acute coronary syndromes following proximal aorto-saphenous anastomoses with the symmetry bypass connector device. Journal of the American College of Cardiology, 2004, 43, 133-139.	1.2	36
270	Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. Journal of the American College of Cardiology, 2003, 41, 360-370.	1.2	310

#	Article	IF	Citations
271	Lysine-Phosphatidylcholine Adducts in Kringle V Impart Unique Immunological and Potential Pro-inflammatory Properties to Human Apolipoprotein(a). Journal of Biological Chemistry, 2003, 278, 52841-52847.	1.6	116
272	Immunomodulatory Effects of Statins: Mechanisms and Potential Impact on Arteriosclerosis. Journal of the American Society of Nephrology: JASN, 2002, 13, 1673-1681.	3.0	109
273	Noninvasive imaging of oxidized Low-Density Lipoprotein in atherosclerotic plaques with tagged oxidation-specific antibodies. American Journal of Cardiology, 2002, 90, L22-L27.	0.7	50
274	Non-invasive imaging of vulnerable plaques by molecular targeting of oxidized LDL with tagged oxidation-specific antibodies. Journal of Cellular Biochemistry, 2002, 87, 138-146.	1.2	18
275	Common femoral artery anatomy is influenced by demographics and comorbidity: Implications for cardiac and peripheral invasive studies. Catheterization and Cardiovascular Interventions, 2001, 53, 289-295.	0.7	124
276	Relationship between the heparin management test and the HemoTec activated clotting time in patients undergoing percutaneous coronary intervention. Journal of Thrombosis and Thrombolysis, 2001, 11, 217-221.	1.0	3
277	Human-Derived Anti-Oxidized LDL Autoantibody Blocks Uptake of Oxidized LDL by Macrophages and Localizes to Atherosclerotic Lesions In Vivo. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 1333-1339.	1.1	197
278	Circulating Autoantibodies to Oxidized LDL Correlate With Arterial Accumulation and Depletion of Oxidized LDL in LDL Receptorâ€“Deficient Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 95-100.	1.1	147
279	Measuring Circulating Oxidized Low-Density Lipoprotein to Evaluate Coronary Risk. Circulation, 2001, 103, 1930-1932.	1.6	121
280	In Vivo Uptake of Radiolabeled MDA2, an Oxidation-Specific Monoclonal Antibody, Provides an Accurate Measure of Atherosclerotic Lesions Rich in Oxidized LDL and Is Highly Sensitive to Their Regression. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 689-697.	1.1	119
281	The Oxidative Modification Hypothesis of Atherogenesis. Developments in Cardiovascular Medicine, 2000, , 49-74.	0.1	22
282	Radiolabeled MDA2, an oxidation-specific, monoclonal antibody, identifies native atherosclerotic lesions in vivoâ˜†. Journal of Nuclear Cardiology, 1999, 6, 41-53.	1.4	122